NIPH Clinical Trials Search

UMIN ID: C000000374

Registered date:01/04/2006

A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedIgA nephropathy in children
Date of first enrollment1998/08/01
Target sample size20
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)prednisolone+warfarin+dipyridamole for 2 years


Primary OutcomeDisappearance rate of proteinuria
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum2years-old
Age maximum18years-old
GenderMale and Female
Include criteria
Exclude criteria1.Nephrotic syndrome 2.Systemic diseases defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus, etc) 3.Medical history of allergy or hypersensitivity reactions to prednisolone, warfarin or dipyridamole 3.Chronic renal dysfunction 4.Active infectious disease 5.Severe liver disfunction 6.History of corticosteroid and immunosupression administration 7.Pregnancy 8.Judged inappropriate for this study by the physicians

Related Information


public contact
Name Koichi Nakanishi
Address 811-1 Kimiidera Wakayama City Wakayama Japan
Affiliation The Japanese Pediatric IgA Nephropathy of Treatment Study Group Department of Pediatrics, Wakayama Medical University
scientific contact
Name Norishige Yoshikawa
Address 811-1 Kimiidera Wakayama City Wakayama Japan
Affiliation Wakayama Medical University Department of Pediatrics